Flaxseed intervention and reproductive endocrine profiles in patients with polycystic ovary syndrome: an open-labeled randomized controlled clinical trial.
Zahra Najdgholami et al. (2025) · Frontiers in endocrinology
This 12-week open-label randomized controlled trial with 70 women explored whether daily flaxseed intake could shift reproductive hormone patterns in polycystic ovary syndrome (PCOS), a common endocrine condition affecting 6 to 15 percent of women of reproductive age. PCOS involves hyperandrogenism (elevated androgen hormones) and disrupted ovulation, often accompanied by a low or borderline follicle-stimulating hormone (FSH) that limits egg follicles from fully maturing. Flaxseed is a plant-based food rich in phytoestrogenic lignans (plant compounds structurally similar to estrogen) and omega-3 fatty acids, both proposed to influence the hormone pathways governing follicle development and gonadotropin balance.
Seventy women diagnosed with PCOS at a clinic in Ahvaz, Iran were randomly assigned to 12 weeks of either 30 grams of daily milled flaxseed added to salads, yogurt, or cold drinks, combined with standard diet and exercise guidance, or the same lifestyle guidance without flaxseed. Blood tests measuring FSH, luteinizing hormone (LH), anti-Mullerian hormone, estradiol, DHEAS, and androstenedione were drawn at baseline and after 12 weeks using enzyme immunoassays and chemiluminescent assays, timed to each participant's menstrual cycle phase where applicable.
FSH rose significantly more in the flaxseed group than in controls (treatment effect 0.87, 95% CI 0.086-1.75, p=0.027), meaning flaxseed users saw a measurably larger increase in this follicle-stimulating hormone than those on lifestyle changes alone. The ratio of LH to FSH also dropped significantly with flaxseed (treatment effect -0.341, 95% CI -0.63 to -0.08, p=0.031), a lower ratio pointing toward more balanced gonadotropin secretion, since an elevated LH/FSH ratio is a hallmark of PCOS. No significant between-group changes appeared for AMH, LH alone, estradiol, DHEAS, or androstenedione, indicating flaxseed's measured effect was specific to FSH and its ratio to LH rather than the broader hormone panel. Weight, BMI, lipids, and blood sugar stayed similar between groups, and no adverse events were reported, suggesting the 30-gram daily dose was well tolerated over the 12 weeks.
The authors propose that flaxseed's omega-3 fatty acids and lignans may support follicle-stimulating hormone receptor activity and gonadotropin regulation, though this mechanism was not directly tested in the trial. The open-label design, unavoidable for a dietary intervention, the single-center setting, and the absence of testosterone and insulin measurements limit how broadly the results extend. The authors identify larger, longer randomized trials incorporating androgen and insulin outcomes as the needed next step for confirming flaxseed's role in PCOS management.
Effects of chamomile and -theanine beverage on menstrual pain, menstrual symptoms, mood, and sleep quality in young women experiencing primary dysmenorrhea: A randomized, double-blind, placebo-controlled study.
Ziqing Soh et al. (2025) · Journal of food and drug analysis
This double-blind, randomized, placebo-controlled trial with 30 young Malaysian women explored whether a beverage combining chamomile and l-theanine could ease primary dysmenorrhea - menstrual cramping that occurs without any underlying pelvic disease. Chamomile (Matricaria recutita) is a flowering herb long used as a calming remedy; the study intervention used a standardized flower extract of it. L-theanine is a non-protein amino acid concentrated in tea leaves (Camellia sinensis), used in supplements to support relaxation. The trial paired both in a functional beverage (CTT) and tested it against a chamomile-flavored placebo (non-CTT) to see whether the combination eased pain, mood, and sleep during menstruation.
Thirty women aged 18-30 with primary dysmenorrhea (pain rated at least 4 of 10 on a visual scale across three cycles) were randomly split into a CTT group (480 mg chamomile extract plus 200 mg l-theanine daily) or a non-CTT control group, drinking two 240 mL packs daily - one on waking, one before bed - for five days spanning two days before their period through its third day. Pain was tracked with two 0-10 scales, symptoms with the 18-item Cox Menstrual Symptom Scale, sleep with the Pittsburgh Sleep Quality Index, and mood with the Profile of Mood States.
Compared to their own baseline, women drinking CTT saw pain scores drop by roughly 57% on both pain scales (p<0.001), a large reduction over five days. Eight menstrual symptoms also eased significantly, including lower abdominal pain (down 53%), back pain (down 56%), and irritability (down 45%, all p<0.05). Mood shifted too: depression scores fell 12% and vigor (energy and alertness) rose 62% (p<0.05). On sleep, only "daytime dysfunction" - grogginess, poor concentration, and low energy during the day - improved (down 32%, p<0.05); overall sleep quality, how long it took to fall asleep, and total sleep time did not change significantly. Hemoglobin levels, checked with a finger-prick test, were unaffected in either group, likely because red blood cells take weeks to months to regenerate, too slow to show up in five days. Interestingly, the placebo group also felt calmer on a few measures, which the researchers link to the shared chamomile scent and flavor rather than to any active ingredient.
For young women managing primary dysmenorrhea without relying on NSAIDs, a short course of this chamomile-l-theanine beverage appears to meaningfully ease pain and several physical and emotional symptoms, with no reported side effects. Because chamomile and l-theanine were only tested together, it is not yet clear how much each contributes individually, and the tiny sample (15 per group) and single five-day cycle mean the results are preliminary. Longer trials spanning multiple cycles, larger and more diverse groups, and a scent-neutral placebo are needed before firmer conclusions can be drawn.